AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

This study is looking for people with certain types of blood cancer, mainly lymphoma. To join, you would generally need to have a confirmed diagnosis of Hodgkin Lymphoma or specific types of Non-Hodgkin Lymphoma, such as PTCL, ALCL, or AITL.

Depending on which part of the study you might join, there are different age requirements. Some parts are for adults aged 18 and over, while one part might include teenagers aged 12 and above, provided they weigh at least 40 kg. You would also need to be able to carry out your daily activities reasonably well and have healthy enough organs, like your kidneys and liver.

For most groups, your cancer would have needed to come back after previous treatments or not have responded well to them. Some parts of the study also require you to have had specific previous treatments. Additionally, doctors will need to be able to take a small sample of your cancer tissue for testing.

Taking part in this study would involve regular visits to the clinic for medical check-ups. You would receive the study medication, AZD3470, which is taken by mouth, either on its own or together with another anti-cancer medicine called pembrolizumab. Doctors would monitor you closely for any side effects and to see how the treatment is affecting your cancer. This includes blood tests, physical exams, and possibly scans.

Some parts of the study involve finding the best dose of AZD3470, which means the dose might be increased gradually. You might also be asked to provide a new tissue sample (biopsy) during the study if your doctors think it's needed and possible. The exact number of visits, tests, and the total duration would depend on which part of the study you are in and how you respond to the treatment, but ongoing follow-up would be part of your participation.